




## 1.0 PURPOSE

This method describes the procedure to assess Drug Substance (DS),



## 2.0 SCOPE

This method applies for the analysis of



in the

cGMP Quality Control Laboratory.

## 3.0 REFERENCED DOCUMENTS

Document #	Title
FRM-0089	QC Column Tracking Form
FRM-0120	General Quality Control Sample Submission Form
FRM-0180	Quality Control Solution Preparation Form
FRM-0260	HPLC/UHPLC Usage and Maintenance Log
FRM-0727	Analysis of mRNA purity by Size-based RPIP SOP-0996 Assay Performance Worksheet
SOP-0017	Maintaining a RNase Free Work Environment
SOP-0022	Good Documentation Practices
SOP-0033	Out of Specification (OOS)
SOP-0079	Sample Submission and Sample Tracking Procedures in the GMP Quality Control Laboratory
SOP-0081	Preparation of Solutions and Samples in the GMP-Quality Control Laboratory
SOP-0082	Data Review and Reporting in the GMP Quality Control Laboratory
SOP-0227	Operation and Maintenance
SOP-0242	Operation and Maintenance of System
SOP-0243	Operation of
SOP-0271	Quality Control HPLC/GC Column Monitoring
SOP-0274	Use of Quality Control Laboratory Notebooks
SOP-0403	QC Operations Procedure

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Document #	Title
SOP-0409	Quality Control Invalid Assay Procedure
SOP-0820	Reconstitution of Lyophilized Drug Product

#### 4.0 RESPONSIBILITIES

Department/ Functional Area	Responsibility
Department Manager or Designee	<ul style="list-style-type: none"> <li>Ensuring that laboratory personnel are properly trained on this procedure.</li> <li>Ensuring that all procedures outlined in this document are followed.</li> </ul>
Quality Control Personnel	<ul style="list-style-type: none"> <li>Following safe operation and maintenance practices outlined within this document.</li> <li>Executing this procedure as described and following good documentation practices per <b>SOP-0022</b>.</li> <li>Documenting daily operation and maintenance activities in the corresponding instrument logbook using <b>FRM-0260</b>.</li> <li>Documenting and monitoring column use per <b>SOP-0271</b> and <b>FRM-0089</b>.</li> <li>Documenting assay information using <b>FRM-0727</b> or in a laboratory notebook per <b>SOP-0274</b>.</li> <li>Preparing solutions per <b>SOP-0081</b> and documenting preparation using <b>FRM-0180</b> or in <b>FRM-0180</b> per <b>SOP-0403</b>.</li> <li>Maintaining an RNase free work environment as per <b>SOP-0017</b>.</li> <li>Reporting any instrument malfunction, safety concerns or incidents to Area Managers.</li> </ul>

#### 5.0 DEFINITIONS

Term	Definition
AUC	Area under the curve
cGMP	Current Good Manufacturing Practices
DP	Drug Product
HPLC	High Performance Liquid Chromatography
IP	Ion Pair
LNP	Lipid Nanoparticle

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Term	Definition
mRNA	Messenger ribonucleic acid
PPE	Personal Protective Equipment
RP	Reverse Phase
RT	Retention time
SDS	Safety Data Sheet
UHPLC	Ultra-High-Performance Liquid Chromatography
UV	Ultraviolet
VWD	Variable wavelength detector
Wt	Weight
xg	Times gravity

## 6.0 EQUIPMENT AND MATERIALS

**NOTE:** Equivalent equipment, consumables, reagents and materials can be used provided the reagent grade or classification is maintained.

### Materials

Materials	Vendor or Supplier	Catalog Number
Sterile [REDACTED] Microcentrifuge tubes (do not use [REDACTED] tubes)	[REDACTED]	[REDACTED]
Column: [REDACTED]	[REDACTED]	[REDACTED]
Glass media bottles of various volumes	N/A	N/A
Graduated cylinders of various volumes	N/A	N/A
[REDACTED]		
HPLC [REDACTED]	[REDACTED]	[REDACTED]
HPLC Caps	[REDACTED]	
[REDACTED] pipette tips	[REDACTED]	
Acetonitrile	[REDACTED]	
[REDACTED] (HPLC Grade)	[REDACTED]	
[REDACTED]	[REDACTED]	
[REDACTED]	[REDACTED]	
[REDACTED]	[REDACTED]	
[REDACTED]	[REDACTED]	
[REDACTED]	[REDACTED]	

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

## Equipment

Equipment	Vendor or Supplier	Catalog Number
UHPLC		
variable adjustable pipets, capable of measuring (recommended: )		
Pipetter		
Analytical Balance		
Stir Plate		
Calibrated Timer	N/A	N/A

## 7.0 SAFETY

- 7.1. Wear the appropriate PPE when working in the cGMP Quality Control laboratory.
- 7.2. Refer to chemical specific SDS for additional safety information.

## 8.0 PROCEDURE

8.1.

8.1.1.

**NOTE:** Solutions, samples, and standards can be prepared at different volumes and amounts if final concentrations are maintained.

8.1.2.

8.1.2.1.

8.1.2.2.

8.1.2.3.

8.1.2.4.

8.1.3.

8.1.3.1.

8.1.3.2.

8.1.3.3.

8.1.3.4.

8.1.3.5.

8.1.4.

8.1.4.1.

8.1.4.2.

8.1.4.3.

8.1.4.4.

8.1.5.

8.1.5.1.

8.1.5.2.

8.1.5.3.

8.1.6.

8.1.6.1.

8.1.6.2.

8.1.6.3.

8.1.7.

8.1.7.1.

8.1.7.2.

8.1.7.3.

8.1.7.4.

8.2.

8.2.1.

8.2.2.

8.2.3.

8.3. [REDACTED]

8.3.1. [REDACTED]

8.3.2. [REDACTED]

8.4. [REDACTED]

8.4.1. [REDACTED]

8.4.2. [REDACTED]

8.4.3. [REDACTED]

8.4.4. [REDACTED]

8.5. [REDACTED]

**NOTE:** The target final sample concentration is [REDACTED]

8.5.1. [REDACTED]

8.5.2. [REDACTED]

8.5.3. [REDACTED]

8.5.4. [REDACTED]

8.5.5. [REDACTED]

8.5.6. [REDACTED]

8.5.7. [REDACTED]

8.5.8. [REDACTED]

8.5.9. [REDACTED]

8.5.10.

8.5.11.

8.5.12.

8.5.13.

8.6.

8.6.1.

8.6.1.1.

8.6.1.2.

8.6.1.3.

8.6.2.

8.6.2.1.

8.6.2.2.

8.6.3.

8.6.3.1.



**Table 6: Instrument Method Parameters**

Parameter	Setting
Instrument:	
Column:	
Acquisition/Run Time:	
Flow Rate:	
Detection:	
Injection Volume:	
Draw Speed:	
Dispense Speed:	
Column Temperature:	
Precolumn Temperature:	
Post column Temperature:	
Autosampler Temperature:	
Needle Wash Settings:	

**Table 7: [REDACTED] for SOP-0996**

Time (min)	Flow Rate	%MPA	%MPB	Curve

**8.6.4. [REDACTED]**

**8.6.4.1. [REDACTED]**

**8.6.4.1.1. [REDACTED]**

**8.6.4.1.2. [REDACTED]**

**Table 8:** [REDACTED]

Time (min)	Flow Rate	%MPA	%MPB	Curve
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

8.6.4.2. [REDACTED]

8.6.4.2.1. [REDACTED]

8.6.4.2.2. [REDACTED]

8.6.4.3. [REDACTED]

8.6.4.4. [REDACTED]

8.6.4.5. [REDACTED]

**Table 9: Recommended Sample Sequence**[illegible]

### 8.6.5.

#### 8.6.5.1.

### 8.6.5.2.

8.6.5.3. [REDACTED]

8.7. [REDACTED]

8.7.1. [REDACTED]

8.7.1.1. [REDACTED]

8.7.1.2. [REDACTED]

8.7.1.3. [REDACTED]

8.7.1.4. [REDACTED]

8.7.2. [REDACTED]

8.7.2.1. [REDACTED]

8.7.2.2. [REDACTED]

8.7.2.3. [REDACTED]

8.7.3. [REDACTED]

8.7.3.1. [REDACTED]

8.7.3.2. [REDACTED]

8.7.3.3. [REDACTED]

8.7.3.4. [REDACTED]

8.8. [REDACTED]

8.8.1. [REDACTED]

8.8.1.1.

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]} * [REDACTED]$$

8.8.1.2.

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]} * [REDACTED]$$

8.8.1.3.

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]} * [REDACTED]$$

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]} * [REDACTED]$$

[REDACTED]

8.8.2.

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]}$$

[REDACTED]

[REDACTED]

$$= \frac{[REDACTED]}{[REDACTED]} * [REDACTED]$$

8.8.3. [REDACTED]

[REDACTED] = [REDACTED] \* [REDACTED]

8.8.4. [REDACTED]

[REDACTED] = [REDACTED]

8.9. [REDACTED]

8.9.1. [REDACTED]

**Table 10: System Suitability Acceptance Criteria**

Parameter	Acceptance Criteria
[REDACTED]	[REDACTED]
	[REDACTED]
	[REDACTED]
	[REDACTED]
	[REDACTED]
[REDACTED]	

8.10. **Sample Acceptance Criteria**

8.10.1. [REDACTED]

**Table 11: Sample Acceptance Criteria**

Parameter	Acceptance Criteria

8.11.

8.11.1.

8.11.2.

8.11.3.

8.11.4.

8.11.4.1.

8.11.4.2.

8.11.4.3.

8.11.4.4.

8.11.4.5.

8.11.4.6.

8.11.4.7.

8.11.4.8.

8.11.5.

8.11.5.1.

8.11.5.2.

8.11.6.

8.11.7.

## 9.0 ATTACHMENTS

- 9.1. Attachment 1: Representative Diluent Blank Chromatogram
- 9.2. Attachment 2: Representative Diluent Blank Chromatogram with background subtraction
- 9.3. Attachment 3: Representative Sensitivity Solution
- 9.4. Attachment 4: Representative Reference Standard / DS Sample Chromatogram (full view and zoom)
- 9.5. Attachment 5: Representative DP / LNP Sample Chromatogram (full view and zoom)


## 10.0 REVISION HISTORY

Revision #	Effective Date	Change Details	Author
1.0	Refer to Veeva Header for Effective Date	New Document	



**ATTACHMENT 1: Representative Diluent Blank Chromatogram**


(Page 1 of 1)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

**ATTACHMENT 2: Representative Diluent Blank Chromatogram with background subtraction**


(Page 1 of 1)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

### **ATTACHMENT 3: Representative Sensitivity Solution**


(Page 1 of 1)



This document cannot be used to support any marketing authorisation application  
Released under Regulation (EC) No 1049/2001 of  
ema.europa.eu

**ATTACHMENT 4: Representative Reference Standard / DS Sample Chromatogram (full view and zoom)**


(Page 1 of 1)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

**ATTACHMENT 5: Representative DP / LNP Sample Chromatogram (full view and zoom)**

(Page 1 of 1)



CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Document Approvals  
Approved Date: 09 Oct 2020

Approval Verdict: Approved	<div>Quality Control Approval 08-Oct-2020 13:31:47 GMT+0000</div>
QA Approval Verdict: Approved	<div>Quality Assurance Approval 08-Oct-2020 18:00:02 GMT+0000</div>

This document cannot be used to support any marketing authorisation application and any extensions or variations thereof  
Released under Regulation (EC) No 1049/2001 on 15 November 2021  
ema.europa.eu